- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- Analysis
- Focus Articles
- Related Articles4 new
- Instablogs
- StockTalks
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
SNY Market Currents
more »
-
May 15 Amylin (AMLN) +6% to $27.19 on reports that it's attracted multiple suitors. Leerink Swann analysts reckon Sanofi (SNY) and Merck (MRK) will emerge as the strongest bidders, and predict a sale price in the mid-$30 a share, although it could go higher if there's a bidding war for the biotech firm.
1 Comment[On the Move, M&A, Healthcare]
SNY in Focus
more »
SNY Related Articles
more »
SNY News
more »
-
at CNBC.com (Tue, 11:46PM)
-
at MarketWatch.com (May 1, 2012)
-
at CNBC.com (Apr 25, 2012)
-
at CNBC.com (Apr 13, 2012)
-
at CNBC.com (Apr 5, 2012)
SNY Press Releases and Filings
more »
-
Business Wire (Apr 27, 2012)
-
Business Wire (Apr 27, 2012)
-
PR Newswire (Apr 19, 2012)
-
PR Newswire (Jan 19, 2012)
-
PR Newswire (Jan 10, 2012)
SNY Latest Transcript
more »
-
Fri, Apr 27Popular searches: sanofi, dividend, lemtrada, acquisitions, africa, merial, novartis, one, particularly, allegra.
SNY Cramer
more »
SNY Instablog posts
more »
SNY vs. ETF Alternatives
Company Description
We are a global biotechnology company dedicated to making a major impact on the lives of people with serious diseases. Our broad product and service portfolio is focused on rare genetic disease disorders, renal disease, orthopaedics, cancer, transplant and immune disease, and diagnostic and... More
